Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$922K Buy
18,235
+2,002
+12% +$123K 0.01% 1011
2026
Q1
$1.06M Sell
16,233
-163
-1% -$11.9K 0.01% 854
2025
Q4
$1.32M Sell
16,396
-158
-1% -$12.7K 0.01% 708
2025
Q3
$1.36M Buy
16,554
+13,967
+540% +$1.21M 0.01% 700
2025
Q2
$236K Sell
2,587
-8,046
-76% -$719K ﹤0.01% 1423
2025
Q1
$973K Sell
10,633
-946
-8% -$82.6K 0.01% 730
2024
Q4
$986K Buy
11,579
+1,284
+12% +$113K 0.02% 643
2024
Q3
$901K Sell
10,295
-1,554
-13% -$131K 0.02% 670
2024
Q2
$935K Sell
11,849
-144,928
-92% -$11.9M 0.03% 615
2024
Q1
$14.2M Buy
156,777
+36,944
+31% +$3.37M 0.3% 120
2023
Q4
$10.5M Buy
119,833
+18,725
+19% +$1.56M 0.26% 126
2023
Q3
$8.54M Buy
+101,108
New +$9.13M 0.26% 118

Other funds holding DOX

Vident Advisory's DOX Position: Q2 2026 in Review

Vident Advisory increased its Amdocs (DOX) stake by 12% in Q2 2026, buying an estimated $123K and bringing the position to 18,235 shares worth $922K. The position accounts for 0.01% of the portfolio, ranked #1011.

Vident Advisory first reported a position in DOX in Q3 2023 and has held it in 12 quarters since. The position peaked at $14.2M in Q1 2024. 447 funds tracked by Wall St. Rank hold DOX as of Q2 2026.

  • Vident Advisory held 18,235 shares of Amdocs worth $922K as of Q2 2026.
  • Vident Advisory bought 2,002 Amdocs shares in Q2 2026, an estimated $123K.
  • Amdocs made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1011 holding.
  • Vident Advisory first reported a position in Amdocs in Q3 2023 and has held it in 12 quarters since.
  • Vident Advisory's Amdocs position peaked at $14.2M in Q1 2024.
  • 447 funds tracked by Wall St. Rank held Amdocs as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.